Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia

Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL). The first-in-class covalent BTK inhibitor, ibrutinib, produces durable responses in most CLL patients; however, complete responses ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Muhowski, Elizabeth M., Ravikrishnan, Janani, Gordon, Britten, Yu, Lianbo, Misra, Shrilekha, Walker, Brandi, Eathiraj, Sudharshan, Sampath, Deepa, Rogers, Kerry A., Byrd, John C., Woyach, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664697/
https://www.ncbi.nlm.nih.gov/pubmed/36380319
http://dx.doi.org/10.1186/s13045-022-01386-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664697/
https://www.ncbi.nlm.nih.gov/pubmed/36380319
http://dx.doi.org/10.1186/s13045-022-01386-1

Ejemplares similares